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Abstract
Background: Over-diagnosis and treatment of prostate cancer has been a major problem in prostate cancer care
and management. Currently the most relevant prognostic factor to predict a patient’s risk of death due to prostate
cancer is the Gleason score of the biopsied tissue samples. However, pathological analysis is subjective, and the
Gleason score is only a qualitative estimate of the cancer malignancy. Molecular biomarkers and diagnostic tests
that can accurately predict prostate tumor aggressiveness are rather limited.
Method: We report here for the first time the development of a nanoparticle test that not only can distinguish
prostate cancer from normal and benign conditions, but also has the potential to predict the aggressiveness of
prostate cancer quantitatively. To conduct the test, a prostate tissue lysate sample is spiked into a blood serum or
human IgG solution and the spiked sample is incubated with a citrate-protected gold nanoparticle solution. IgG is
known to adsorb to citrate-protected gold nanoparticles to form a “protein corona” on the nanoparticle surface.
From this study, we discovered that certain tumor-specific molecules can interact with IgG and change the
adsorption behavior of IgG to the gold nanoparticles. This change is reflected in the nanoparticle size of the assay
solution and detected by a dynamic light scattering technique. Assay data were analyzed by one-way ANOVA for
multiple variant analysis, and using the Student t-test or nonparametric Mann-Whitney U-tests for pairwise analyses.
Results: An inverse, quantitative correlation of the average nanoparticle size of the assay solution with tumor
status and histological diagnostic grading was observed from the nanoparticle test. IgG solutions spiked with
prostate tumor tissue exhibit significantly smaller nanoparticle size than the solutions spiked with normal and
benign tissues. The higher grade the tumor is, the smaller the nanoparticle size is. The test particularly revealed
large differences among the intermediate Grade 2 tumors, and suggested the need to treat them differently.
Conclusion: Development of a new nanoparticle test may provide a quantitative measure of the prostate cancer
aggressiveness. If validated in a larger study of patients with prostate cancer, this test could become a new
diagnostic tool in conjunction with Gleason Score pathology diagnostics to better distinguish aggressive cancer
from indolent tumor.
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Background
Prostate cancer (PCa) is the most common malignancy
and the second leading cause of cancer death in Ameri-
can men. Using digital rectal examination (DRE) com-
bined with the PSA (prostate specific antigen) test, most
prostate cancer cases are now detected at an early stage.
However, due to the lack of accurate tests to distinguish
aggressive cancers from indolent tumors, prostate cancer
is often over-treated. Post-surgery pathology analysis
revealed that 30% of tumors removed by radical prosta-
tectomy are deemed clinically insignificant and would
not have required such invasive treatment [1]. Over-
diagnosis and treatment of low-risk prostate cancer has
serious and long-lasting side effect: as high as 70% of
the patients who receive radical prostatectomy treatment
will suffer a loss of sexual potency that cannot be reme-
died by drugs such as sildenafil citrate [2]. Currently the
most relevant prognostic factor to predict a patient’s
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risk of death due to PCa is the Gleason score of the
biopsied tissue samples. However, pathological analysis
is subjective, and the Gleason score is only a qualitative
estimate of the cancer malignancy. Molecular biomar-
kers and diagnostic tests that can accurately predict the
prostate tumor aggressiveness are rather limited.
We herein report on our work to develop a simple
nanoparticle-serum protein adsorption test that not only
can distinguish prostate cancer from normal and benign
conditions, but also has the potential to predict the
aggressiveness of prostate cancer quantitatively. This
test is based on a new platform bioanalytical technology,
nanoparticle-enabled dynamic light scattering assay
(NanoDLSay) that we developed earlier [3-8]. NanoDL-
Say detects protein analytes by monitoring the nanopar-
ticle size change upon specific binding or non-specific
adsorption of target protein analytes to the gold nano-
particles (AuNPs). Citrate-protected AuNPs have a layer
of negative charge on the surface because of the citrate
ions. Proteins tend to adsorb to citrate-protected AuNPs
through electrostatic interactions, Au-N and Au-S bond-
ing to form a so-called “protein corona” (Figure 1)
[9-11]. The size of the protein corona varies depending
on the type and the size of the proteins adsorbed to the
AuNPs. For example, as illustrated in the Figure 1, the
adsorption of a protein complex or oligomer will cause
larger nanoparticle size increase than an individual pro-
tein monomer. The protein-AuNP interaction may also
cause AuNP cluster formation, if multiple binding sites
are present in the proteins or protein complexes. These
differences can be readily detected and discerned by
dynamic light scattering (DLS) analysis, a technique
used routinely for particle size measurement.
Blood serum contains a large number and a large
quantity of various serum proteins. Recently, we pro-
posed a serum-AuNP adsorption assay for cancer bio-
marker discovery based on a simple hypothesis that
there may be some differences in the serum proteins
adsorbed to the AuNPs between cancer and non-cancer
samples [8]. To conduct the assay, a serum solution is
simply mixed with a citrate-protected AuNP solution
and the average particle size of the AuNP solution
before and after sample incubation is measured by DLS.
From our previous study conducted on mice models [8],
we discovered that there is a significant difference in the
serum-adsorbed AuNP size between mouse serum
Figure 1 A schematic illustration of “protein corona” formed on the surface of AuNPs upon protein adsorption. The size of the protein
corona varies depending on the type and the size of the proteins adsorbed to the AuNPs. As indicated, the adsorption of a protein complex or
oligomer will cause larger nanoparticle size increase than an individual protein monomer. The protein-AuNP interaction may also cause AuNP
cluster formation if multiple binding sites are present on a protein or protein complex. These differences can be readily detected and discerned
according to the dynamic light scattering measurement.
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samples with and without prostate tumor. The average
particle size of the assay solution is substantially smaller
for mice carrying large tumor grown from orthotopically
injected PC3 cells compared to healthy control mice
and mice bearing smaller tumor grown from LnCaP
cells [8]. However, from the previous study, the same
difference was not observed from human serum samples
with and without prostate cancer.
The biggest challenge for cancer biomarker discovery
and early cancer detection is that at early stage, the
amount of specific molecules that are released from the
tumor to the blood is very small. In the mice model
study we conducted previously [8], the relative tumor
mass versus body weight of the PC3 and LnCaP mice
was approximately 5% and 0.3%, respectively. These
ratios would correspond to a tumor mass of 2.5 Kg and
150 g in a human patient with a body weight of 50 Kg.
Such tumor sizes are far exceeding the tumor size from
human patients with early stage cancer. The volume of
a high grand human cancer is about 3.5-4.0 cc [12]. The
only human setting with prostate cancer > 150 g would
be the metastatic setting. It is therefore not surprising
that the difference found from mice models was not
observed from human serum samples.
In order to apply the AuNP adsorption test on human
patient samples, we introduced a unique new experiment
in this study to increase the amount of cancer-specific
components by spiking the blood serum samples with
primary tumor tissue extracts prior to the AuNP adsorp-
tion test. We hypothesize that when tumor-associated
molecules are released to the blood, this may cause cer-
tain molecular changes to occur in the serum and such
molecular changes are reflected in the AuNP-serum
adsorption assay. By spiking a tumor tissue lysate directly
to the blood, the concentration of tumor-associated
molecules in the blood is synthetically increased, and as a
result, molecular change of the serum similar to what
occurs in in vivo may be more easily and clearly observed.
We have now indeed observed the very same differ-
ence from the human serum samples that we observed
previously from mice models: the average particle size
of human serum samples spiked with prostate tumor tis-
sue is substantially smaller than the serum samples
spiked with normal and benign prostate tissue lysates in
the serum-AuNP adsorption test. It was discovered that
this difference is caused by the interactions between
tumor-specific molecules and the circulating immuno-
globulin G (IgG) proteins in the blood serum. Such
interactions changed the adsorption behavior of IgGs to
the AuNPs, and subsequently, the average nanoparticle
size of the assay solution. By spiking prostate tissue
lysates into a pure human IgG solution, we observed the
same particle size differences between normal, benign
and prostate tumor tissues as observed from the blood
serum samples. Furthermore, there is a significant,
quantitative inverse correlation of the average nanoparti-
cle size of the assay solution with tumor histological
diagnostic grading. The current study is a preliminary in
vitro report. If validated in a larger study of patients
with prostate cancer, this serum protein (IgG)-AuNP
adsorption assay can potentially become a new prognos-
tic tool in conjunction with Gleason Score pathology




Citrate-protected gold nanoparticle (AuNP) (15708-9)
was purchased from Ted Pella Inc. (Redding, CA). The
average diameter of the citrate AuNP is 100 nm and the
concentration of the nanoparticle is 10 pM. Pure human
IgG (ab91102) was purchased from Abcam (http://www.
abcam.com). All human serum samples were purchased
from Asterand Solutions (http://www.asterand.com).
Tissue lysate samples were purchased from Protein Bio-
technologies (http://www.proteinbiotechnologies.com).
The protocol used for preparing the tissue lysates can
be found from the website of Protein Biotechnologies
and is also summarized in the Additional file 1 along
with the clinical data of tissue samples. Data presented
in each graph (Figures 2 and 3) were based on the
assays of samples that were collected using the same
method, stored under the same conditions, thawed, pre-
pared, and tested at the same time under the exactly
same assay conditions. All human tissue and serum
samples used in this study are de-identified, archived
specimens. The University of Central Florida IRB com-
mittee approved the use of these commercially acquired
samples with exemption.
Sample preparation and assay methods
To prepare tissue lysate-spiked serum samples or pure
IgG solutions, 1 μL lysate at a total protein concentra-
tion of 1 mg/mL was mixed with 20 μL serum or IgG
solution (concentration of 1 mg/mL in phosphate buffer,
pH 7.4). The mixed solution was set at 4°C overnight for
tissue lysate-spiked serum samples, and 30 minutes at
room temperature for tissue lysate-spiked IgG samples
before nanoparticle assay was conducted. To conduct
the AuNP adsorption assay, 2 μL sample solution was
mixed with 40 μL AuNP solution. The serum-AuNP
solution was incubated for 8 min, and the IgG-AuNP
solution was incubated for 3 min at room temperature
before particle size was measured. All assays were con-
ducted in duplicate and the error bars in each plot
represent the standard error of the assay.
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Dynamic light scattering (DLS) analysis
Particle size analysis of the assay solutions was con-
ducted using an automatic DLS instrument, NDS1200,
from Nano Discovery Inc. (http://www.nanodiscover-
yinc.com). This system is equipped with a 12-sample
holder carousel to allow automatic measurement of 12
samples within 5-6 minutes. The measurement error for
the pure AuNP solution with an average diameter of
100 nm is ± 2 nm. All DLS measurements were con-
ducted at an ambient temperature of 25°C. The polydis-
persity index of the pure citrate-protected AuNPs and
all AuNP assay solutions (i.e., the mixed solution of
AuNPs and samples) falls in the range of 0.3-0.5. There
is no significant difference between pure AuNP and
AuNP assay solution.
Statistical analysis
Where possible, data were analyzed by one-way
ANOVA for multiple variant analysis, and using Student
t-test or nonparametric Mann-Whitney U -tests for
pairwise analyses. The results of these analyses are
included in the Additional file 1 with appropriate p
values and statistical parameters (n, mean, SD and/or
SEM). Linear regression analysis for data presented in
Figure 2 was done with significance determined by com-
paring slope deviation from zero and the R squared
value for fit on each of the assay sets presented.
Results and discussions
We first conducted the serum-AuNP adsorption assay
on a series of blood serum samples spiked with different
Figure 2 The AuNP adsorption assay results of serum spiked with different prostate tissue lysates. All samples were prepared by spiking
1 μL tissue lysate into 20 μL serum. All spiked samples were incubated at 4°C overnight before assay was conducted. Particle size was measured
after 8 minutes of serum-AuNP incubation. A and B: the assay results of 8 serum (normal healthy donor = 4; BPH = 4) spiked with 4 prostate
tissue lysates from normal, tissue with Grade 1, Grade 2, and Grade 3 prostate adenocarcinoma. The Gleason scores of the three tumor tissues
are: 4(2 + 2), 5(2 + 3), and 9(5 + 4), respectively. A is the scatter-plot of all 32 samples and B is an expansion of A with 6 samples that have
relatively smaller average particle sizes. Linear regression analysis of each sample set suggests that all but BPH21 sample mixes (R squared =
0.2061, p = 0.1382) had significant linear inverse correlations between the average particle size seen in the nanoparticle assay and the increasing
tumor grade/staging, with goodness of fit R squared values ranging from 0.7406, p = 0.0003 for N17 to 0.9734, p < 0.0001 for BPH 23 sample
sets. C and D: two sets of assay results of two different serum samples spiked with tissue lysates from normal healthy donors, BPH patients, and
PCa donors. In the first set (C), PCa2 tissue lysate was spiked to the serum at two different ratios: 1:20 and 1:100 (tissue lysate:serum, v/v).
Statistically significant differences were found in the assay results between the normal controls (mean 196.1 ± 11.3SD) and BPH samples (mean
183.8 ± 6.4SD; p = 0.0078, Student t-test), BPH and PCa samples (mean 158.4 ± 16.3SD; p = 0.0051, Mann-Whitney U-test), and normal and PCa
samples (p < 0.0001, Student t-test).
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types of prostate tissue lysates (Figure 2). In a first set of
experiment, we tested 8 male serum samples (4 from
normal donors and 4 from patients with abnormal but
non-cancerous benign prostate hyperplasia, BPH) spiked
with 4 different prostate tissue lysates that were from
normal healthy control, tissue with Grade 1 (Gleason
Score 4(2 + 2)), Grade 2 (Gleason Score 5(2 + 3)), and
Grade 3 (Gleason Score 9(5 + 4)) prostate adenocarci-
noma (Figure 2A and 2B, plot B is an expansion of plot
A). All tissue lysates were prepared in the same buffer
(a modified RIPA buffer) using exactly the same proto-
col and all tissue lysates have the same total protein
concentration of 1 mg/mL. Among the 8 sets of serum
samples, 7 sets exhibited a clear trend of decreased aver-
age particle size when the serum was spiked with pros-
tate tumor tissue lysates. The average particle size is
inversely related to the grade of the tumor. We tested
additional sets of normal and tumor tissue lysates-spiked
serum samples (including data presented here, total
approximately 100 samples made from the combination
of 10 serum samples spiked with 10 different tissue
lysates), and the tests all showed the same trend of
nanoparticle size reduction. BPH21 is the only exception
observed throughout the whole study so far. Linear
regression analyses suggest that all but BPH21 sample
mixes (R squared = 0.2061, p = 0.1382) had significant
linear inverse correlations between the average particle
size seen in the nanoparticle assay and the increasing
tumor grade/staging, with goodness of fit R squared
values ranging from 0.7406, p = 0.0003 for N17 to
0.9734, p < 0.0001 for BPH 23 sample sets.
In a second set of experiment, we tested two sets of
normal serum samples spiked with normal, BPH, and
PCa tissue lysates, respectively. In the first set of sam-
ples (Figure 2C), the two PCa tissue lysates are both
from Grade 3 tumor: PCa1 has a Gleason Score of (5 +
4) and PCa2 has a Gleason Score of (4 + 5). Again, the
spiking of PCa tissue lysates to the serum led to a much
smaller average particle size of the assay solution.
Between the two BPH tissue lysates, one behaved like
the normal tissue, and another one caused the particle
size decrease of the assay solution; however, the
decrease is smaller than the PCa tissue lysates. There is
also a difference between the two PCa tissue samples:
PCa2 caused more substantial particle size decrease
than PCa1, even though PCa1 has a Gleason score of (5
+ 4) while PCa2 has a Gleason score of (4 + 5). In con-
trast to the pathological analysis, the AuNP adsorption
assay we conducted here suggests that PCa2 is more
aggressive than PCa1. We also observed a concentra-
tion-dependent effect: PCa2 tissue lysate was spiked into
the same serum in 1:20 and 1:100 (lysate:serum, v/v)
ratio, respectively. With an increased amount of tissue
lysate spiked into the serum, the particle size decreasing
effect caused by the tumor tissue lysate is more
dramatic.
The second set of samples showed very similar results
(Figure 2D): the BPH tissue lysate-spiked samples
showed slight nanoparticle size reduction compared to
the normal samples, while 4 out of 5 tumor tissue
lysate-spiked samples showed substantial nanoparticle
size reduction compared to the normal tissue lysates.
The most aggressive tumor among the five samples, #15
from a donor of age 47 with a Gleason score of 8,
showed the largest nanoparticle size reduction. On the
other hand, sample #11, a tumor with a Gleason score
of 7, exhibited a similar behavior as a normal tissue
sample. Even with the small number of samples tested
in this study, a marked discrepancy can already be seen
between the new test results and the pathology reports.
Overall, statistically significant differences were found in
the assay results between the normal controls (mean
196.1 ± 11.3SD), BPH (mean 183.8 ± 6.4SD), and PCa
samples (mean 158.4 ± 16.3SD). The p value for the
group pairs, normal-PCa, BPH-PCa, and normal-BPH, is
< 0.0001, 0.0051, and 0.0078, respectively.
We want to emphasize that the observed difference
between prostate cancer and non-cancer samples is not
due to the buffer effect, because all tissue lysates sam-
ples were prepared using exactly the same buffer and
the same procedure. We also tested serum samples
spiked with the pure buffer solution (a modified RIPA
buffer) that was used to prepare the tissue lysates, and
no effect from the buffer on the serum-AuNP adsorp-
tion assay was observed at all.
Results obtained from our previous study on mice
models and the current studies on human serum samples
Figure 3 The AuNP adsorption assay results of human IgG
solution spiked with different prostate tissue lysates. All
samples were prepared by spiking 1 μL tissue lysate into 20 μL IgG
solution. The concentration of IgG solution was 1 mg/mL in
phosphate buffer (10 mM, pH 7.4). The prepared samples were
incubated at r.t. for 30 min before assay was conducted. Particle size
was measured after 3 minutes of human IgG-AuNP incubation. The
‘normal range’ threshold (red dotted line) was set as 2SD below the
mean of the normal control group analyses.
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suggest the following: (1) When prostate tumor develops,
certain chemicals and biomolecules are released from the
tumor site to the blood and these chemicals/biomole-
cules interact with certain proteins in the blood, changing
the serum protein adsorption to the AuNPs. (2) The
more aggressive the prostate tumor is, the more substan-
tial the serum molecular change is. In the search of a
molecular mechanism to explain the observed results, a
critical question to be answered is: what is the most rele-
vant protein in the blood serum that has been changed
by the tumor tissue chemicals/biomolecules?
Based on our own and others’ studies [8,9], we sug-
gested that in the serum-AuNP adsorption assay, the
major components of the protein corona formed on the
AuNPs are abundant serum proteins. Circulating immu-
noglobulin G (IgG) is one of the most abundant blood
serum proteins, with a typical concentration in the
range of 5-15 mg/mL. IgG is known to have strong affi-
nity towards citrate-protected AuNPs, a property that
has been used for decades as a general method to pre-
pare AuNP immunoprobes through a simple adsorption
process [13]. If IgG is indeed a major component in the
protein corona adsorbed to the AuNPs, the observed
difference between cancer and non-cancer samples
could then have been due to the unique interactions
between tumor-specific molecules and IgG.
To test this hypothesis, we conducted the same AuNP
adsorption assay on pure human IgG solution spiked
with 42 prostate tissue lysates. Remarkably, we observed
the same particle size differences between tumor, benign
and normal tissue-spiked IgG solution (Figure 3, n is
the number of tissue samples tested). Furthermore, the
average particle size of the assay solution is inversely
related to the tumor grade. The normal and the most
aggressive Grade 3 tumor can be clearly differentiated
without any overlap. Most benign and Grade 1 tumor
tissues gave similar results as normal tissues, but with
two samples resembling a more aggressive tumor profile.
The assay results of 11 Grade 2 tumor tissues extend
over a wide range, reflecting exactly the ambiguous
aggressiveness of the Grade 2 tumor. According to the
pathological reports, all these Grade 2 tumors are the
same or similar; however, based on the nanoparticle
test, there are substantial differences between these
intermediate grade tumors, and should be treated differ-
ently. If the ‘normal range’ threshold is set as 2SD
below the mean of the normal control group (red dotted
line), the Grade 2 and 3 tumors are detected with 100%
sensitivity from the nanoparticle test. However, most
low-grade prostate tumors are slow-growing tumors and
may not need to be treated with the radical prostatect-
omy surgery. To determine the best cut-off value/range
for treatment selection, a more extensive clinical study
based on a larger data set needs to be conducted.
There are two hypotheses that may explain the nano-
particle size reduction caused by the spiking of tumor tis-
sue lysates into serum or pure IgG solution. One is that
the molecules released from the tumor tissue compete
with the serum proteins/molecules to bind with AuNPs.
For some reasons, the tumor tissue-associated molecules
adsorbed to the AuNPs are smaller than the serum pro-
teins, and also smaller than the normal tissue-associated
molecules, leading to the observed nanoparticle size
reduction of tumor tissue-spiked serum or human IgG
solution. However, this hypothesis is not supported by
the results of a control experiment: we conducted the
AuNP adsorption assay directly on tumor tissue and nor-
mal tissue lysate solutions, and found that the tumor tis-
sue lysates generally led to a slightly larger nanoparticle
size increase than the normal tissue lysates (by about 10
nm). A second hypothesis is the more plausible reason:
certain tumor tissue-specific molecules interact with
serum IgG to form complexes, and this interaction chan-
ged the IgG adsorption to AuNPs. A model as illustrated
in Figure 4 is proposed to explain the observed difference
between cancer and non-cancer samples. IgG, either as a
monomer or oligomer, causes AuNP cluster formation
when adsorbed to the AuNPs. When mixing IgG solution
or serum with tumor tissue lysates, the specific binding
of tumor-specific molecules with IgG inhibits the cross-
linking of the AuNPs, leading to a decreased average
nanoparticle size of the assay solution.
This mechanism suggests that serum IgG, by interact-
ing with tumor-associated, enhanced or altered mole-
cules, may be providing a natural immune defense
against prostate cancer spreading in the blood. If this
Figure 4 A mechanistic model to explain the observed
difference between normal and prostate cancer samples.
Human IgG, either as a monomer or oligomer, causes AuNP cluster
formation when adsorbed to the AuNPs. When mixing IgG solution
or serum with tumor tissue lysates, the specific binding of tumor-
associated molecules with IgG inhibits the crosslinking of the
AuNPs, leading to a decreased average nanoparticle size of the
assay solution.
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natural defense system is exhausted, cancer metastasis
can begin. This model, very interestingly, echoes well
with the findings on the association between cancer and
the immune system/functions [14-16].
The above model also implicates that the best serum
biomarker for early detection of aggressive prostate can-
cer may be found from the complexes with serum IgG,
not as individual molecules in the blood. If the tumor-
specific molecules are interacting with circulating IgGs
at a typical antibody-antigen binding constant of 1010
M-1, a simple calculation (assuming the serum IgG con-
centration is at an average value of 10 mg/mL) reveals
that the concentration of IgG-complexed tumor biomar-
kers would be about 600,000 times of the free biomarker
molecules in the blood. This means at early stage of
cancer development, almost all cancer biomarker mole-
cules released from the tumor site to the blood are com-
plexed to the serum IgGs. Current bioassays are set
almost exclusively to detect target protein analytes in
individual molecular forms, without considering the
complex behavior of a protein analyte. This is perhaps
one reason to explain why there are so many inconsis-
tencies in cancer biomarker research.
Conclusions
In summary, we reported here the development of a sim-
ple nanoparticle assay that may be used for quantitative
assessment of the prostate tumor aggressiveness. The sig-
nificant inverse correlation of the average nanoparticle
size of the assay solution with tumor histological diag-
nostic grading suggests that the nanoparticle assay could
potentially provide a more accurate diagnostic tool to
assess the tumor aggressiveness than the current diagnos-
tic practices. Based on the results reported here and our
previously reported studies on mice models, a large scale
clinical study to validate the new nanoparticle test for
prostate cancer diagnosis is justified. If successfully vali-
dated, the reported new test can bring an immediate
solution to the long-standing over-treatment problem in
prostate cancer care. Current assay still requires the use
of biopsied tissue samples. It would be ideal if aggressive
prostate cancer can be detected early using only blood
samples. We are conducting further studies at the pre-
sent to identify the specific tumor molecules that are
complexed with the serum IgGs. We expect sensitive
serum biomarkers for early detection of aggressive pros-
tate cancer to be discovered from these studies.
Additional material
Additional file 1: The protocol used for tissue lysate preparation,
the clinical data of the tissue samples, and the statistical analysis
results of the assay data are included in the Supplementary
Information.
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